Skip to content
CancerIndex

Publication

Triptonide enhances DNA damage by inhibiting TRIP13‑mediated DNA repair and synergizes with bortezomib to suppress multiple myeloma.

Fen He, Junjun Li, Lijun Peng, Hongyan Zhao, Maoyou Lu, Ruixin Gao, Siqi Wang, Yu Chen, Ruihan Tang, Zhengguo Li, Linlin Zhang, Xinyu Zhang, Qianhao Li, Weihui Chen, Jiayu Liu, Cong Luo, Xi Zeng, Jiliang Xia

International journal of oncologySep 1, 2026PMID 42464653doi:10.3892/ijo.2026.5919 PMC13387127Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 15, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260915-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Multiple myeloma (MM) is a malignant disorder of plasma cells. Combinations of bortezomib (BTZ) with other therapeutic agents remain the mainstay of MM treatment. However, the rising incidence of drug resistance among patients with MM underscores an urgent need for novel therapeutic strategies. The…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.